Matrix metalloproteases as a pharmacological target in cardiovascular diseases

European Review for Medical and Pharmacological Sciences

Volumn 19, Issue 14, 2015, Pages 2583-2589

  Hopps, E ^a   Caimi, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cardiovascular diseases; Matrix metalloproteases (MMPs); Tissue inhibitors (TIMPs)

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; ANTIHYPERTENSIVE AGENT; MATRIX METALLOPROTEINASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; ENZYME ACTIVITY; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN TARGETING; ANIMAL; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEM; ENZYMOLOGY; HYPERTENSION; METABOLIC SYNDROME X; PROCEDURES; TRENDS;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; DIURETICS; DRUG DELIVERY SYSTEMS; HUMANS; HYPERTENSION; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; METABOLIC SYNDROME X;

EID: 84942328929     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. NEWBY AC. Metalloproteinases expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2008; 28: 2108-2014.
2. RAFFETTO JD, KHALIL RA. Matrix metalloproteinases and their Inhibitors in vascular remodeling and vascular disease.Biochem Pharmacol 2008; 75: 346-359.
3. BOURBOLIA D, STETLER-STEVENSON WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Sem Cancer Biol 2010; 20: 161-168.
4. JAISWAL A, CHHABRA A, MALHOTRA U, KOHLI S, RANI V. Comparative analysis of human matrix metalloproteinases: Emerging therapeutic targets in diseases. Bioinformation 2011; 6: 23-30.
5. AMALINEI C, CARUNTU ID, BALAN RA. Biology of metalloproteinases. Rom J Morphol Embryol 2007; 48: 323-334.
6. KAR S, SUBBARAM S, CARRICO PM, MELENDEZ JA. A critical link between free radicals, matrix remodeling and degenerative disease. Respir Physiol Neurobiol 2010; 174: 299-306.
7. AL-HAMODI Z, ISMAIL IS, SAIF-ALI R, AHMED KA, MUNIANDY S. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol 2011; 10: 23.
8. HANSSON J, VASAN RS, ANLOV J, INGELSSON E, LIND L, LARSSON A, MICHAELSSON K, SUNDSTROM J. Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial Infarction, and cause-specific mortality: Cohort Study. PLoS ONE 2011; 6: e16185.
9. VIAPPIANI S, NICOLESCU AC, HOLT A, SAWICKI G, CRAWFORD BD, LEÓN H, VAN MULLIGEN T, SCHULZ R. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 2009; 77: 826-834.
10. BREW K, NAGASE H. The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversity. Biochim Biophys Acta 2010; 1803: 55-71.
11. HOPPS E, LO PRESTI R, MONTANA M, NOTO D, AVERNA MR, CAIMI G. Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome. J Investig Med 2013; 61: 978-983.
12. CAIMI G, FERRARA F, MONTANA M, MURATORI I, AMATO C, CANINO B, LO PRESTI R, HOPPS E. Behaviour of the plasma concentration of gelatinases and their tissue inhibitors in subjects with venous leg ulcers. Clin Hemorheol Microcirc 2014 Aug 26. [Epub ahead of print]
13. CASTRO MM, KANDASAMY AD, YOUSSEF N, SCHULZ R. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res 2011; 64: 551-560.
14. CASTRO MM, TANUS-SANTOS JE, GERLACH RF. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011; 64: 567-572.
15. CERON CS, CASTRO MM, RIZZI E, MONTENEGRO MF, FONTANA V, SALGADO MC, GERLACH RF, TANUS-SANTOS JE. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br J Pharmacol 2010; 160: 77-87.
16. MARTINEZ ML, LOPES LF, COELHO EB, NOBRE F, ROCHA JB, GERLACH RF, TANUS-SANTOS JE. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J Cardiovasc Pharmacol 2006; 47: 117-122.
17. MARÇAL DM, RIZZI E, MARTINS-OLIVEIRA A, CERON CS, GUIMARAES DA, GERLACH RF, TANUS-SANTOS JE. Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 35-44.
18. IZIDORO-TOLEDO TC, GUIMARAES DA, BELO VA, GERLACH RF, TANUS-SANTOS JE. Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells. Naunyn Schmiedebergs Arch Pharmacol 2011; 383: 547-554.
19. MUÑOZ-PACHECO P, ORTEGA-HERNÁNDEZ A, CARO-VADILLO A, CASANUEVA-ELICEIRY S, ARAGONCILLO P, EGIDO J, FERNÁNDEZ-CRUZ A, GÓMEZ-GARRE D. Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure. J Hypertens 2013; 31: 2309-2318.
20. LI MJ, HUANG CX, OKELLO E, YANHONG T, MOHAMED S. Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Can J Cardiol 2009; 25: 523-526.
21. KAMIOKA M, ISHIBASHI T, SUGIMOTO K, UEKITA H, NAGAI R, SAKAMOTO N, ANDO K, OHKAWARA H, TERAMOTO T, MARUYAMA Y, TAKEISHI Y. Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways. J Atheroscler Thromb 2010; 17: 590-600.
22. ONAL IK, ALTUN B, ONAL ED, KIRKPANTUR A, OZ SG, TURGAN C. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med 2009; 20: 369-372.
23. SCHIEFFER B, BUNTE C, WITTE J, HOEPER K, BOGER RH, SCHWEDHELM E, DREXLER H. Comparative Comparative effects of AT1-antagonism and angiotensinconverting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004; 44: 362-368.
24. FONTANA V, SILVA PS, BELO VA, ANTONIO RC, CERON CS, BIAGI C, GERLACH RF, TANUS-SANTOS JE. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol 2011; 109: 130-137.
25. YOKOTA T, OSANAI T, HANADA K, KUSHIBIKI M, ABE N, OIKAWA K, TOMITA H, HIGUMA T, YOKOYAMA J, HANADA H, OKUMURA K. Effects of telmisartan on markers of ventricular remodeling in patients with acute myocardial infarction: comparison with enalapril. Heart Vessels 2010; 25: 460-468.
26. MIYAZAKI S, KASAI T, MIYAUCHI K, MIYAZAKI T, AKIMOTO Y, TAKAGI A, AIHARA K, KAWAMURA M, SUWA S, KOJIMA S, SUMIYOSHI M, DAIDA H. Changes of matrix metalloproteinase-9 level is associated with left ventricular remodeling following acute myocardial infarction among patients treated with trandolapril, valsartan or both. Circ J 2010; 74: 1158-1164.
27. CIPOLLONE F, FAZIA M, IEZZI A, PINI B, CUCCURULLO C, ZUCCHELLI M, DE CESARE D, UCCHINO S, SPIGONARDO F, DE LUCA M, MURARO R, BEI R, BUCCI M, CUCCURULLO F, MEZZETTI A. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation 2004; 109: 1482-1488.
28. CLANCY P, SETO SW, KOBLAR SA, GOLLEDGE J. Role of the angiotensin converting enzyme 1/angiotensin II/angiotensin receptor 1 axis in interstitial collagenase expression in human carotid atheroma. Atherosclerosis 2013; 229: 331-337.
29. ZHANG W, HAN Y, MENG G, BAI W, XIE L, LU H, SHAO Y, WEI L, PAN S, ZHOU S, CHEN Q, FERRO A, JI Y. Direct renin inhibition with aliskiren protects against myocardial ischemia/reperfusion injury by activating nitric oxide synthase signaling in spontaneously hypertensive rats. J Am Heart Assoc 2014; 3: e000606.
30. MALIK J, STULC T, CESKA R. Matrix metalloproteinases in isolated hypercholesterolemia. Int Angiol 2005; 24: 300-303.
31. ERCAN E, TENGIZ I, ALTUGLU I, SEKURI C, ALIYEV E, ERCAN HE, AKIN M. Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia. Kardiol Pol 2004; 60: 454-458.
32. KALELA A, LAAKSONEN R, LEHTIMÄKI T, KOIVU TA, HÖYHTYÄ M, JANATUINEN T, PÖLLÄNEN P, VESALAINEN R, SAIKKU P, KNUUTI J, NIKKARI ST. Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases. Am J Cardiol 2001; 88: 173-175.
33. KOH KK, AHN JY, JIN DK, HAN SH, KIM HS, CHOI IS, AHN TH, SHIN EK, JEONG EM. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. Int J Cardiol 2004; 97: 239-244.
34. KOH KK, SON JW, AHN JY, HYUNG SK, CHOI YM, JEONG EM, PARK GS, CHOI IS, SHIN EK. Comparative effects of diet and statin on NO bioactivity and matr ix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: e19-e23.
35. QU HY, XIAO YW, JIANG GH, WANG ZY, ZHANG Y, ZHANG M. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 2009; 26: 958-964.
36. CEVIK C, NUGENT K, MEYERROSE G, OTAHBACHI M, IZGI C, LYTE M, FISH RD. Rosuvastatin therapy does not affect serum MMP-13 or TIMP-1 levels in hypercholesterolemic patients. Tex Heart Inst J 2011; 38: 229-233.
37. GUO H, SHI Y, LIU L, SUN A, XU F, CHI J. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice. Arch Med Res 2009; 40: 345-351.
38. QIN YW, YE P, HE JQ, SHENG L, WANG LY, DU J. Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Westernstyle diet" by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacol Sin 2010; 31: 1350-1358.
39. BHATT LK, VEERANJANEYULU A. Enhancement of matrix metalloproteinase 2 and 9 inhibitory action of minocycline byaspirin: an approach to attenuate outcome of acute myocardial infarction in diabetes. Arch Med Res 2014; 45: 203-209.
40. LIU O, JIA L, LIU X, WANG Y, WANG X, QIN Y, DU J, ZHANG H. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. PLoS One 2012; 7: e51707.
41. GUO S, STINS M, NING M, LO EH. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc Dis 2010; 30: 290-296.
42. CHUANG SY, YANG SH, CHEN TY, PANG JH. Cilostazol inhibits matrix invasion and modulates the gene expressions of MMP-9 and TIMP-1 in PMA-differentiated THP-1 cells. Eur J Pharmacol 2011; 670: 419-426.
43. KASAHARA Y, NAKAGOMI T, MATSUYAMA T, STERN D, TAGUCHI A. Cilostazol reduces the risk of hemorrhagic infarction after administration of tissue-type plasminogen activator in a murine stroke model. Stroke 2012; 43: 499-506.
44. SCHUYLER CA, TA NN, LI Y, LOPES-VIRELLA MF, HUANG Y. Insulin treatment attenuates diabetes-increased atherosclerotic intimal lesions andmatrix metalloproteinase 9 expression in apolipoprotein E-deficient mice. J Endocrinol 2011; 210: 37-46.
45. GUO J, DHALIWALL JK, CHAN KK, GHANIM H, AL KOUDSI N, LAM L, MADADI G, DANDONA P, GIACCA A, BENDECK MP. In vivo effect of insulin to decrease matrix metalloproteinase-2 and-9 activity after arterial injury. J Vasc Res 2013; 50: 279-288.
46. ESFAHANIAN N, SHAKIBA Y, NIKBIN B, SORAYA H, MALEKIDIZAJI N, GHAZI-KHANSARI M, GARJANI A. Effect of metformin on the proliferation, migration, and MMP-2 and-9 expression of human umbilical vein endothelial cells.Mol Med Rep 2012; 5: 1068-1074.
47. HWANG YP, JEONG HG. Metformin blocks migration and invasion of tumour cells by inhibition of matrix metalloproteinase-9 activation through a calcium and protein kinase Calpha-dependent pathway: phorbol-12-myristate-13-acetate-induced/extracellular signal-regulated kinase/activator protein-1. Br J Pharmacol 2010; 160: 1195-1211.
48. RONG JZ, LI L, FEI F, LUO L, QU Y. Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer. Exp Clin Cancer Res 2013; 32: 32.
49. HUANG J, ANG L, LIU MQ, HU HG, WANG J, ZOU Q, ZHAO Y, ZHENG L, ZHAO M, WU ZS. Serum and tissue expression of gelatinase and Twist in breast cancer. Eur Rev Med Pharmacol Sci 2014; 18: 2662-2669.
50. ZHANG J, ZHANG DI, JIAO XI, DONG Q. S100A4 regulates migration and invasion in hepatocellular carcinoma HepG2 cells via NF-kB-dependent MMP-9 signal. Eur Rev Med Pharmacol Sci 2013; 17: 2372-2382.
51. CHANG K, FRANCIS SA, AIKAWA E, FIGUEIREDO JL, KOHLER RH, MCCARTHY JR, WEISSLEDER R, PLUTZKY J, JAFFER FA. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging. Arterioscler Thromb Vasc Biol 2010; 30: 1933-1939.
52. UNAL R, YAO-BORENGASSER A, VARMA V, RASOULI N, LABBATE C, KERN PA, RANGANATHAN G. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. J Clin Endocrinol Metab 2010; 95: 2993-3001.
53. HANEFELD M, PFÜTZNER A, FORST T, KLEINE I, FUCHS W. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study. Cardiovasc Diabetol 2011; 10: 65.
54. MADSEN EL, BRUUN JM, SKOGSTRAND K, HOUGAARD DM, CHRISTIANSEN T, RICHELSEN B. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects. Metabolism 2009; 58: 946-953.
55. RESS C, TSCHONER A, CIARDI C, LAIMER MW, ENGL JW, STURM W, WEISS H, TILG H, EBENBICHLER CF, PATSCH JR, KASER S. Influence of significant weight loss on serum matrix metalloproteinase (MMP)-7 levels. Eur Cytokine Netw 2010; 21: 65-70.
56. PAPAZOGLOU D, PAPATHEODOROU K, PAPANAS N, PAPADOPOULOS T, GIOKA T, KABOUROMITI G, KOTSIOU S, MALTEZOS E. Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 levels in severely obese patients: what is the effect of weight loss? Exp Clin Endocrinol Diabetes 2010; 118: 730-734.
57. ROBERTS CK, WON D, PRUTHI S, KURTOVIC S, SINDHU RK, VAZIRI ND, BARNARD RJ. Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors. J Appl Physiol 2006; 100: 1657-1665.